MedTrace Logo

Amino Acid Nutrition in the Critically-ill

NCT02865408 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-06

No results posted yet for this study

Summary

Enhancing the anabolic effect of nutrition in critically ill patients by administering exogenous amino acids.

Conditions

Interventions

DIETARY_SUPPLEMENT

Peptamen 1.5% via enteral

Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.

DIETARY_SUPPLEMENT

Prosol 20% IV to 1.75g/kg/day

Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.

DIETARY_SUPPLEMENT

Prosol 20% IV to 2.5g/kg/day

Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.

Sponsors & Collaborators

  • Arnold Kristof

    lead OTHER

Principal Investigators

  • Arnold S Kristof, MDCM, FRCPC · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2026-01-28
Completion
2026-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865408 on ClinicalTrials.gov